This is how much £1K invested in GSK shares 5 years ago would be worth today

GlaxoSmithKline plc (LON: GSK) is a popular stock. But has it been a good investment?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) is a very popular stock among UK investors. Along with other well-known FTSE 100 names, such as Lloyds Bank, BP, and Royal Dutch Shell, the pharmaceutical giant can be found within a lot of private investor portfolios.

Have GSK shares been a good investment over the last five years though? Let’s take a look at the stock’s five-year return.

GSK has smashed the FTSE 100

On 18 December 2014, GSK shares traded between 1,316p and 1,361p. Had you paid the average of these two prices and picked up some shares at 1,339p, an investment of £1,000 would have got you 74 shares (the cost would have been £991 plus trading commissions).

Now, over the last five years, Glaxo shares have had their ups and downs. So, had you purchased five years ago, there would have been a few occasions where you were sitting on unrealised capital losses. For example, in September 2015, the stock fell to near 1,200p. 

Today, however, GSK’s share price stands at 1,796p meaning those 74 shares would now be worth around £1,329. That equates to a capital gain of around 34% (or 6.1% on an annualised basis) which is certainly not a bad result.

By contrast, the FTSE 100 has produced a capital gain of approximately 18% (3.3% per year) over that time period. So, from a capital gain perspective, GSK shares have easily beaten the market.

Dividends have turbocharged returns

Of course, when you add dividends into the equation, GSK’s returns have been much higher. Glaxo has paid a large dividend over the last five years and this has had a powerful impact on investor returns.

Looking at GSK’s dividend history, had you purchased the stock on 18 December 2014, you would have picked up dividends of 382p per share so far. As such, a holding of 74 shares would have generated dividends of £283.

If we add this figure to the value of the shares (which assumes you didn’t reinvest your dividends), the total comes to £1,612.

So, overall, had you invested £1,000 in GSK shares five years ago, your money would now be worth £1,612 (not counting trading commissions). That equates to a total gain of 62.7% over five years or 10.2% on an annualised basis. I see that as a pretty decent return – if you earn 10%+ on your money every year, you’ll become wealthy pretty quickly.

Two key takeaways 

To my mind, there are a couple of key takeaways from this GSK analysis. 

Firstly, rewards come to those who are patient. GSK shares have had their ups and downs over the last five years. Those who have stuck it out have made good money. 

Secondly, dividends really can have a huge impact on stock market investment returns. Excluding dividends, GSK shares returned just over 6% per year. However, when you include dividends, the stock generated a return of more than 10% per year, which is an excellent return.

All too often, investors ignore dividends when investing in shares because they see them as negligible. Dividends shouldn’t be underestimated though. Over time, they can be an extremely powerful wealth creation tool.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in GlaxoSmithKline, Lloyds Bank and Royal Dutch Shell. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Lloyds Banking Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 market-beating international investment funds for a Stocks and Shares ISA

It always pays to look for new ways to add extra diversity to a Stocks and Shares ISA. I think…

Read more »

Grey cat peeking out from inside a cardboard box in a house
Investing Articles

Just released: April’s latest small-cap stock recommendation [PREMIUM PICKS]

We believe the UK small-cap market offers a myriad of opportunities across a wide range of different businesses and industries.

Read more »

Fireworks display in the shape of willow at Newcastle, Co. Down , Northern Ireland at Halloween.
Investing Articles

The Anglo American share price soars to £25, but I’m not selling!

On Thursday, the Anglo American share price soared after mega-miner BHP Group made an unsolicited bid for it. But I…

Read more »

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »